Xavier Q.
- Country
- France
- Department
- Oncology
Research Overview
- Phase III Randomized Controlled Trial of Pembrolizumab with Platinum-Based Chemotherapy Versus Pembrolizumab Monotherapy in First-Line Treatment of NSCLC with PD-L1 ≥50%
- Tarlatamab plus Durvalumab versus Durvalumab Alone in Patients with Extensive-Stage Small Cell Lung Cancer Following Platinum-Etoposide Therapy
- A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Data & Insights
Has run more than one trial at 212 of 433 partner sites.
Specializations
Thoracic Oncology
The clinical research activity is centered on non-small cell lung cancer, small cell lung cancer, and other advanced thoracic malignancies, including locally advanced and metastatic disease. The portfolio also includes studies in pleural mesothelioma and unresectable pleural mesothelioma, with interest in treatment-resistant and biomarker-defined populations.
- Non-small cell lung cancer
- Small cell lung cancer
- Pleural mesothelioma
- EGFR-mutated lung cancer
- Locally advanced thoracic malignancies
Therapeutic interests include targeted therapy, immunotherapy, and approaches for patients with progressive or recurrent thoracic cancer.
Breast Cancer and Hormone-Driven Malignancies
Another major area of involvement is breast cancer, especially HER2-positive, HER2-negative, HER2-low, and triple-negative breast cancer. The research landscape also includes hormone receptor-positive disease, endocrine-resistant disease, and metastatic settings with central nervous system involvement.
- Metastatic breast cancer
- Triple-negative breast cancer
- HER2-positive breast cancer
- Hormone receptor-positive breast cancer
- Endocrine-resistant breast cancer
The therapeutic focus includes endocrine therapy, anti-HER2 treatment, antibody-drug conjugates, and biomarker-guided strategies in advanced breast malignancy.
Gastrointestinal and Hepatobiliary Cancers
The investigator is also active in gastrointestinal cancers, with work spanning colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, esophageal cancer, pancreatic cancer, and biliary tract cancer. Disease settings include both locally advanced and metastatic presentations, as well as recurrent and unresectable tumors.
- Colorectal cancer
- Gastric and gastroesophageal junction cancer
- Pancreatic adenocarcinoma
- Biliary tract cancer
- Esophageal cancer
Therapeutic interests extend to chemotherapy, targeted agents, perioperative treatment, and management of advanced gastrointestinal disease with high unmet need.
Gynecologic Oncology
Clinical trial involvement includes a broad range of gynecologic cancers, particularly ovarian cancer, endometrial cancer, cervical cancer, and uterine sarcoma. The portfolio covers recurrent, metastatic, and high-risk localized disease, with attention to molecularly defined subgroups.
- Ovarian cancer
- Endometrial cancer
- Cervical cancer
- Uterine sarcoma
- Peritoneal and fallopian tube cancer
The therapeutic emphasis includes PARP inhibition, immunotherapy, and treatment strategies for recurrent or platinum-resistant gynecologic malignancies.
Urologic, Head and Neck, and Rare Solid Tumors
Additional activity spans prostate cancer, urothelial carcinoma, head and neck squamous cell carcinoma, and selected rare solid tumors such as sarcoma, neuroendocrine tumors, glioblastoma, and mesothelioma. These studies include advanced, recurrent, and biomarker-selected disease states.
- Prostate cancer
- Urothelial carcinoma
- Head and neck squamous cell carcinoma
- Soft tissue sarcoma
- Neuroendocrine tumors
Therapeutic domains include androgen receptor-directed therapy, radiotherapy combinations, immuno-oncology, and treatments for uncommon or difficult-to-treat solid tumors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.